Association of TT virus primary infection with rhinitis in a newborn.

of tuberculosis disappeared with no evidence of recurrence at 1-year follow-up. Drug interactions between Rif and protease inhibitors have prompted clinical studies of HIV-infected patients that have documented the efficacy of Rib as a substitute for Rif in the 6-month antituberculous regimen [2–4]. Intolerance to Rif is not rare and could be another indication for Rib. The tolerance profile of Rib is distinct from that of Rif, and there is no indication that cross-toxicity is of concern [5]. In conclusion, a regimen that contains Rib could be the first-choice alternative for the treatment of patients with tuberculosis who are intolerant to Rif.